Aligos Q2 FY26 net loss narrows 91% to $1.5 million
ALGS•Cash position and trial update
Cash, cash equivalents and investments fell to $30.4 million at June 30 from $77.8 million at Dec. 31, excluding a $25 million upfront received in July.
Enrollment finished in the Phase 2 B-SUPREME study of pevifoscorvir sodium; Aligos expects topline data in late Q3 2027 and sees funding through Q4 2026.
Q2 loss narrows as warrant gains offset higher R&D
Aligos Therapeutics posted a Q2 net loss of $1.5 million, narrowing from a $15.9 million loss a year earlier; loss per share improved to $(0.14).
R&D expense climbed to $24.1 million from $14 million, driven by higher third-party costs for the pevifoscorvir sodium Phase 2 trial.
Quarter results included $3 million of income from changes in fair value of 2023 common warrants, while interest and other income slipped to $0.2 million from $1.2 million.
